Population pharmacokinetics of imatinib mesylate in nigerian patients with chronic myeloid leukemia
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Presentation
- By: ADEAGBO, Babatunde (Obafemi Awolowo University, Department of Pharmaceutical Chemistry, Ile-ife, Nigeria)
- Co-author(s): Bolaji, Oluseye (Obafemi Awolowo University, Ile-ife, Nigeria)
Olugbade, Tiwalade (Obafemi Awolowo University, Ile-ife, Nigeria)
Durosinmi, Muheez (Obafemi Awolowo University, Ile-ife, Nigeria)
Bolarinwa, Rahaman (Obafemi Awolowo University, Ile-ife, Nigeria)
Ogungbenro, Kayode (University of Manchester, Manchester, United Kingdom)
Background: Population pharmacokinetic studies of imatinib mesylate in Caucasian and Japanese patients with chronic myeloid leukaemia (CML) have shown inter-subject and inter-population clearance variabilities. However, no pharmacokinetic (PK) study has been conducted in an African population since the introduction of the drug.
Aim: This study.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.